SuperworthCullinan Therapeutics EPS CGEM
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Sep 30, 2024
- −$2.86
- Latest quarter, Q3 FY24
- −$0.69
- Fiscal year 2023
- −$3.71
- −257% on the year before
Cullinan Therapeutics' earnings per share was −$2.86 over the twelve months to Sep 30, 2024.
In its latest quarter, Q3 FY24, it was −$0.69.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2023 | −$3.71 | −257% |
| FY2022 | $2.37 | n/a |
| FY2021 | −$1.52 | n/a |
| FY2020 | −$2.55 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY24 | −$0.69 | n/a | −$2.86 | |
| Q2 FY24 | −$0.75 | n/a | −$3.08 | |
| Q1 FY24 | −$0.86 | n/a | −$3.15 | |
| Q4 FY23 | −$0.56 | n/a | −$3.71 | |
| Q3 FY23 | −$0.91 | n/a | −$3.74 | |
| Q2 FY23 | −$0.82 | −122% | −$3.37 | |
| Q1 FY23 | −$1.42 | n/a | $1.22 | |
| Q4 FY22 | −$0.59 | n/a | $2.37 | |
| Q3 FY22 | −$0.54 | n/a | $2.20 | |
| Q2 FY22 | $3.77 | n/a | $2.34 | |
| Q1 FY22 | −$0.27 | n/a | −$1.79 | |
| Q4 FY21 | −$0.76 | n/a | −$1.52 |
Against its peers
Companies in Biotechnology nearest Cullinan Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CGEMCullinan Therapeutics | n/m | |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| Peer median | $0.70 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Cullinan Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.